Active Trials

Total Trials

Organizations

Events

Turkey

Medical Only (Private)

Reimbursed Care Access

Turkey maintains a restrictive national control regime for classical serotonergic and empathogenic psychedelics: most tryptamines, phenethylamines and classic psychedelic plants/ preparations are scheduled and not available outside authorised research or prosecution exceptions. Medical use of ketamine as an anaesthetic and analgesic is well established in Turkish clinical practice; esketamine (marketed as SPRAVATO in some markets) appears in Turkish product information sources but is not known to be broadly reimbursed by the public social security system (SGK) and is administered under specialist supervision. Other compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are effectively prohibited for general medical use and only accessible in authorised clinical trials or not at all.

Read Full Access Guide View Active Trials

Clinical Trials in Turkey

Unknown statusPhase NA

Dose Low Dose Ketamine in Casesarian

Prospective case-control observational study (n=150) comparing single-dose IV ketamine (0.5 mg/kg), ketamine plus midazolam, and saline placebo in patients undergoing caesarean section to evaluate postpartum depression and postoperative outcomes.

Started: June 1, 2024
Type: observational
Randomized: No
Registry ID: NCT06237569

CompletedPhase IV

Effects of Subanesthetic Dose of Ketamine Given on Postoperative Mood in Patients Undergoing Fractional Curettage

This randomized controlled trial (n=140) investigated the impact of a single subanesthetic dose of ketamine (35mg/70kg) administered intravenously during the induction of propofol/fentanyl anesthesia on acute mood states in women undergoing fractional curettage.

Started: April 1, 2022
Type: interventional
Blinding: triple
Randomized: Yes
Registry ID: NCT05752110

CompletedPhase IV

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

Open-label single-group long-term extension (n=183) assessing long-term safety and tolerability of intranasal esketamine plus SSRI/SNRI in participants with treatment-resistant major depressive disorder who completed prior esketamine study.

Started: April 26, 2021
Type: interventional
Blinding: none
Randomized: No
Registry ID: NCT04829318

CompletedPhase III

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

This Phase III interventional trial (n=676) evaluated flexibly dosed esketamine nasal spray versus quetiapine XR, both with a continuing SSRI/SNRI, in participants with treatment-resistant major depressive disorder.

Started: August 21, 2020
Type: interventional
Blinding: none
Randomized: Yes
Registry ID: NCT04338321

CompletedPhase III

A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE II)

This double-blind, randomized, placebo-controlled trial (n=226) aimed to assess the efficacy and safety of intranasal esketamine 84 milligrams (mg) in addition to comprehensive standard care for rapidly reducing Major Depressive Disorder (MDD) symptoms, including suicidal ideation, in adults at imminent risk for suicide.

Started: June 15, 2017
Type: interventional
Blinding: double
Randomized: Yes
Registry ID: NCT03097133

CompletedPhase III

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Open-label, long-term extension Phase III safety study (n≈1148) of esketamine nasal spray (flexible 28–84 mg dosing) in participants with treatment-resistant depression, induction twice weekly for 4 weeks then individualised maintenance.

Started: June 9, 2016
Type: interventional
Blinding: none
Randomized: No
Registry ID: NCT02782104

Turkey

Reimbursed Care Access

Clinical Trials in Turkey

Dose Low Dose Ketamine in Casesarian

Effects of Subanesthetic Dose of Ketamine Given on Postoperative Mood in Patients Undergoing Fractional Curettage

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE II)

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Research Events

Company

Product

Legal

Turkey

Reimbursed Care Access

Clinical Trials in Turkey

Dose Low Dose Ketamine in Casesarian

Effects of Subanesthetic Dose of Ketamine Given on Postoperative Mood in Patients Undergoing Fractional Curettage

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/​Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide (ASPIRE II)

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression (SUSTAIN-3)

Research Events

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)